论文部分内容阅读
[目的]探讨CLN3基因在卵巢浆液性囊腺癌中的表达特点及与其生物学行为的关系。[方法]采用半定量RT-PCR方法和Western blot方法检测45例卵巢浆液性肿瘤(良性浆液性肿瘤11例,交界性肿瘤11例,浆液性癌23例)和12例正常卵巢组织中CLN3基因表达情况。[结果]卵巢浆液性囊腺癌组织中CLN3mRNA表达为3.04±0.58,交界性卵巢浆液性囊腺瘤组织中表达为1.63±0.43,均明显高于正常卵巢组织和卵巢浆液性囊腺瘤(P<0.01);卵巢浆液性囊腺癌组织CLN3mRNA表达高于交界性卵巢浆液性囊腺瘤(P<0.01);卵巢浆液性囊腺癌患者Ⅰ/Ⅱ期与Ⅲ/Ⅳ期、G1/G2与G3及有无腹水间比较差异有显著性(P<0.05)。[结论]CLN3基因与卵巢浆液性癌的发生发展和预后可能有关,可作为卵巢浆液性癌重要的生物学标志物。
[Objective] To investigate the expression of CLN3 gene in ovarian serous cystadenocarcinoma and its relationship with its biological behavior. [Method] Semi-quantitative RT-PCR and Western blot were used to detect the expression of CLN3 gene in 45 cases of ovarian serous tumors (11 cases of benign serous tumors, 11 cases of borderline tumors, 23 cases of serous carcinoma) and 12 cases of normal ovarian tissues Express the situation. [Results] The expression of CLN3 mRNA in ovarian serous cystadenocarcinoma was 3.04 ± 0.58 and that in borderline ovarian serous cystadenoma was 1.63 ± 0.43, which was significantly higher than that in normal ovarian tissue and ovarian serous cystadenoma (P <0.01). The expression of CLN3mRNA in ovarian serous cystadenocarcinoma was higher than that in borderline ovarian serous cystadenoma (P <0.01). There was no significant difference in the expression of CLN3mRNA between ovarian serous cystadenocarcinomaⅠ / Ⅱ and Ⅲ / Ⅳ, G1 / G2 There was significant difference between G3 and presence or absence of ascites (P <0.05). [Conclusion] The CLN3 gene may be related to the occurrence, development and prognosis of ovarian serous carcinoma and may be used as an important biomarker of ovarian serous carcinoma.